|
|
Agenda
| June 15, 2004 |
| OVERVIEW TALKS – PANEL SESSION |
| 8:20 a.m. |
The Importance of Being Able to Predict Human Sensitivity
Joseph Tomaszewski, Ph.D., Acting Associate Director, Developmental Therapeutics Program, National Cancer Institute |
| 9:00 a.m. |
Toxicology Liabilities and Their Effect on Success Rates in the Pharmaceutical Industry: How Can We Sharpen the Tools That We Have and Forge New Ones?
Richard Robertson, Ph.D., Senior Vice President, Drug Safety and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company |
| 10:00 a.m. |
DMPK - Friend or Foe of Drug Development?
Geoff Tucker, Ph.D., Professor, University of Sheffield |
| 10:40 a.m. |
Development and Application of Computational Toxicology and Informatics Resources at the FDA Center for Drug Evaluation and Research
Joseph Contrera, Ph.D., Director, Informatics and Computational Safety Analysis Staff, Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
| 11:20 a.m. |
Discussion of Overview Talks |
| IN-VITRO AND IN-VIVO DRUG TOXICITY MODELS – PANEL SESSION |
| 1:00 p.m. |
Screening the Receptorome to Discover Molecular Targets Responsible for Drug Toxicities
Bryan Roth, M.D., Ph.D., Professor, Biochemistry, Case Western Reserve University Medical School |
| 1:35 p.m. |
Identification of Serotonin 5-HT2B Receptor Cardiovascular Functions or How Combined Mouse Molecular Genetics and Pharmacology Reinterpret the Toxicology of Fenfluramine (Amphetamine Derived) Anorexigens
Luc Maroteaux, Ph.D., Institut de Génétique de et Biologie Moléculaire de Celluaire, Centre National de la Recherche Scientifique-Institut National de la Santé et de la Recherche Médicale, Strasbourg University |
| 2:10 p.m. |
A Genetic Roadmap for Predictive Toxicology
Guochun Liao, Ph.D., Scientist and Group Leader, Computational Genomics, Roche Palo Alto |
| 2:45 p.m. |
Genetic and Phenotypic Engineering of Mouse Models of Common Human Diseases
Joseph Nadeau, Ph.D., Chair, Department of Genetics, Case Western Reserve University School of Medicine |
| METABONOMICS – PANEL SESSION |
| 3:30 p.m. |
Introductions
Lois Lehman-McKeeman, Ph.D., Research Fellow, Bristol-Meyers Squibb Company |
| 3:50 p.m. |
Metabonomics and Drug Safety Evaluation
Donald Robertson, Ph.D., Director and Research Fellow, Pfizer Global Research and Development |
| 4:25 p.m. |
Mass Spectrometry-Based Metabonomics: Data Analysis and Pathway Mapping
Susan Sumner, Ph.D., Senior Scientist, Paradigm Genetics, Inc. |
| 5:00 p.m. |
Systems Toxicology and the Chemical Effects in Biological Systems Knowledgebase
Michael Waters, Ph.D., Assistant Director, Database Development, National Center for Toxicogenomics, National Institute of Environmental Health Sciences |
| June 16, 2004 |
| ADME – PANEL SESSION |
| 8:15 a.m. |
Use of X-Ray Crystal Structures to Predict Mammalian Cytochrome P450 Function
James Halpert, Ph.D., Professor and Chairman, Department of Pharmacology and Toxicology, University of Texas-Medical Branch |
| 8:50 a.m. |
Physiological Modeling of Drug Interactions
Stephen Hall, Ph.D., Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine |
| 9:25 a.m. |
Structure-Toxicity Relationships as a Tool to Investigate Mechanisms of Drug Toxicity
Sidney Nelson, Ph.D., Professor and Dean, Department of Medical Chemistry, University of Washington School of Pharmacy |
| 10:30 a.m. |
Pharmacogenetics of Drug Conjugating Enzymes
Rebecca Blanchard, Ph.D., Associate Member, Department of Pharmacology, Fox Chase Cancer Center |
| 11:05 a.m. |
Renal Transporters in Predictive ADME
Kathleen Giacomini, Ph.D., Professor and Chair, Department of Biopharmaceutical Sciences, University of California-San Francisco School of Pharmacology |
| 11:40 a.m. |
The Impact of Active Transport on Tissue Distribution of Drugs
Noa Zerangue, Ph.D., Principal Investigator, Xenoport |
| 1:00 p.m. |
The Application of Gene Expression in Toxicology Screening, Mechanistic Elucidation, and Biomarker Identification
Donna Mendrick, Ph.D., Vice President, Toxicogenomics Gene Logic, Inc. |
| DATABASES/DATA ANALYSIS – PANEL SESSION |
| 1:50 p.m. |
Data Analysis Using Structured Biological Knowledge: Experience with a Database of Protein Functional Interactions
Alan Ruttenberg, Ph.D., Lead Software Engineer, Millennium Pharmaceuticals |
| 2:25 p.m. |
Construction of a Human Adverse Effects Database for Modeling Quantitative Structure-Activity Relationships (QSARs)
Naomi Kruhlak, Ph.D., Chemist, Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
| 3:30 p.m. |
Preclinical Predictive ADME and Toxicology Analysis Discussion Groups
These four discussion groups will allow participants to discuss additional areas needed to improve preclinical predictive ADME and Toxicology analysis. |
| June 17, 2004 |
| 8:00 a.m. |
Concurrent Discussion Groups
These discussion groups will allow participants to discuss research needs, new areas that may support goals, and new research groups that need to be brought into predictive testing in the four areas: (1) In-Vitro/In-Vivo Models, (2) ADMET, (3) Toxicogenomics and Metabonomics, and (4) Bioinformatics/Databases. |
| 8:50 a.m. |
Concurrent Discussion Groups (Repeated) |
| 10:00 a.m. |
Next Steps/Closing |
Up to Top
|
